

SEP 26 2002

TECH CENTER 1600/2900



Approved for use through 10/31/2002 GPO:059-001  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
				Application Number	09/830,810
				Filing Date	October 28, 1999
				First Named Inventor	Martin M. Matzuk
				Art Unit	1653
				Examiner Name	J. Olsen
Sheet	1	of	4	Attorney Docket Number	HO-P01925US1

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (If known)			
AA	AA	5801016-	09-01-1998	Morioka et al.	
AB	AB	5547854-	08-20-1996	Donahoe et al.	
AC	AC	5563059-	10-08-1996	Alak et al.	
AD	AD	5661126-	08-26-1997	Donahoe et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (If known)			
AD	BA	-WO98/40483-	09-17-1998	Human Genome Sciences, Inc.	

Examiner Signature		Date Considered	4-9-04
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

25211200.1

Copied from PCT1309830810 on 10-03-2004

SEP 13 2002  
PATENT & TRADEMARK OFFICE

TECH CENTER 1600/2900

PTO/SB/08B (10-01)


Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
				Application Number	09/830,810
				Filing Date	October 28, 1999
				First Named Inventor	Martin M. Matzuk
				Group Art Unit	1653
				Examiner Name	J. Olsen
Sheet	2	of	4	Attorney Docket Number	HO-P01925US1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
D	CA	Elvin, Julia A., et al.; Paracrine Actions of Growth Differentiation Factor-9 in the Mammalian Ovary; Molecular Endocrinology, Vol. 13, No. 6, 1999				
D	CB	Elvin, Julia A., et al.; Molecular Characterization of the Follicle Defects in the Growth Differentiation Factor 9-Deficient Ovary; Molecular Endocrinology, Vol. 13, No. 6; 1999				
D	CC	Matzuk, Martin M., et al.; Transgenic Models to Study the Roles of Inhibins and Activins in Reproduction, Oncogenesis, and Development; Recent Progress in Hormone Research, Vol. 51				
D	CD	Ohsumi, Keita, et al.; Characterization of the Ooplasmic Factor Inducing Decondensation of and Protamine Removal from Toad Sperm Nuclei: Involvement of Nucleoplasmin; Developmental Biology; Vol. 148; 1991				
D	CE	Philpott, Anna, et al.; Nucleoplasmin Remodels Sperm Chromatin in Xenopus Egg Extracts; Cell; Vol. 69; 1992				
D	CF	Matzuk, Martin M., et al.; Different phenotypes for mice deficient in either activins or activin receptor type II; Nature; Vol. 374; 1995				
D	CG	Dong, Jinwen, et al.; Growth differentiation factor-9 is required during early ovarian folliculogenesis; Nature; Vol. 383; 1996				
D	CH	McGrath, Sharon A., et al.; Oocyte-Specific Expression of Growth/Differentiation Factor-9; Molecular Endocrinology; Vol. 9, No. 1; 1995				
D	CI	Kumar, T. Rajendra, et al.; Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility; Nature Genetics; Vol. 15; 1997				
D	CJ	Perreault, Sally D.; Chromatin remodeling in mammalian zygotes; Mutation Research; Vol. 296; 1992				
D	CK	Krohne, Georg, et al.; Immunological identification and localization of the predominant nuclear protein of the amphibian oocyte nucleus; Proc. Natl. Acad. Sci. USA; Vol. 77; 1980				
D	CL	Matzuk, Martin M., et al.; An Inhibin is a tumour-suppressor gene with gonadal specificity in mice; Nature; Vol. 360; 1992				
D	CM	Elvin, Julia A., et al.; Growth differentiation factor-9 stimulates progesterone synthesis in granulosa cells via a prostaglandin E2/EP2 receptor pathway; PNAS; Vol. 97, No. 18; 2000				
D	CN	MacArthur, Craig A., et al.; Npm3: A Novel, Widely Expressed Gene Encoding a Protein Related to the Molecular Chaperones Nucleoplasmin and Nucleophosmin; Genomics; Vol. 42; 1997				
D	CO	Mills, A. D., et al.; An Acidic Protein Which Assembles Nucleosomes in Vitro is the Most Abundant Protein in Xenopus Oocyte Nuclei; J. Mol. Biol.; Vol. 139; 1980				
D	CP	Dingwall, Colin, et al.; Nucleoplasmin cDNA sequence reveals polyglutamic acid tracts and a cluster of sequences homologous to putative nuclear localization signals; The EMBO Journal; Vol. 6, No. 1; 1987				
D	CQ	McLay, David W., et al.; The Ability to Organize Sperm DNA into Functional Chromatin Is Acquired during Meiotic Maturation in Murine Oocytes; Developmental Biology; Vol. 186; 1997				
D	CR	Carabatossos, Mary Jo, et al.; Characterization of Oocyte and Follicle Development in Growth Differentiation Factor-9-Deficient Mice; Developmental Biology; Vol. 204; 1998				
D	CS	Philpott, Anna, et al.; Sperm Decondensation in Xenopus Egg Cytoplasm Is Mediated by Nucleoplasmin; Cell; Vol. 65; 1991				
D	CT	Burglin, Thomas R., et al.; Cloning of nucleoplasmin from Xenopus laevis oocytes and analysis of its developmental expression; Genes & Development; Vol. 1; 1987				

Examiner Signature		Date Considered	4-9-04
--------------------	---	-----------------	--------

SFP 2.3 2002

SEP 26 2002

PTO/SB/608 (04/01)  
U.S. PATENT AND TRADEMARK OFFICE  
DEPT. OF COMMERCE

Approved for use through TDE 01/02/2011 DB51-008

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.</p> <p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>				<p><b>Complete If Known</b></p>	
<p>Application Number</p>		<p>09/830,810</p>			
<p>Filing Date</p>		<p>October 28, 1999</p>			
<p>First Named Inventor</p>		<p>Martin M. Matzuk</p>			
<p>Group Art Unit</p>		<p>1653</p>			
<p>Examiner Name</p>		<p>J. Olsen</p>			
Sheet	3	of	4	<p>Attorney Docket Number</p> <p>HO-P01925US1</p>	

**\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

3

### Complete If Known

Application Number	09/830,810
Filing Date	October 28, 1999
First Named Inventor	Martin M. Matzuk
Art Unit	1653
Examiner Name	Steven Post

Attorney Docket Number HO-P01925US1

RECEIVED  
JUL 14 2003  
TECH CENTER 1600  
2003

### U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
AS	BA	WO-00/24755-A1	05-04-2000	Baylor College of Medicine		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AS	CA	Wu, X., et al.; Zygote arrest 1 (Zar1) is a novel maternal-effect gene critical for the oocyte-to-embryo transition; Nat Genet. 33(2):187 - 191, February 2003	
AS	CB	Matzuk, M.M., et al.; Genetic dissection of mammalian fertility pathways; Nat Cell Biol. Suppl 4:S41 - 49, October 2002	
AS	CC	Varani, S., et al.; Phenotypic effects of knockout of oocyte-specific genes; Ernst Schering Res Found Workshop (41):63 - 79, 2002	
AS	CD	Matzuk, M. M., et al.; Intercellular communication in the mammalian ovary: oocytes carry the conversation. Science 296 (5576):2178 - 2180; June 21, 2002	
AS	CE	Rajkovic, A., et al.; Functional analysis of oocyte-expressed genes using transgenic models. Mol Cell Endocrinol. 187(1-2):5 - 9, February 22, 2002	
AS	CF	Yan, C., et al.; Oosp1 encodes a novel mouse oocytesecreted protein; Genesis 31(3):105 - 110, November 2001	
AS	CG	Lau, A., et al.; Transgenic models in the study of reproduction; Gravit Space Biol Bull. 12(2):75 - 82, May 1999	
AS	CH	Elvin, J.A., et al.; Oocyte-expressed TGF-beta superfamily members in female fertility; Mol Cell Endocrinol 159(1-2):1 - 5, January 25, 2000	
AS	CI	The Sanger Centre, et al.; Toward a Complete Human Genome Sequence; Genome Research 8:1097 - 1108, 1998	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.